PolyPeptide Group

Swiss public CDMO (PPGN.SX). Founded 1952, headquartered in Baar, Switzerland. Operates 6 GMP facilities in Sweden, Belgium, France, USA, and India. Specializes in peptide and oligonucleotide APIs. Claims to manufacture ~50% of commercially approved peptide APIs globally. Provides robust global shipping network supporting pharmaceutical supply chains.

PolyPeptide Group is listed as a CDMO in the peptide supply chain, serving Europe markets from Global. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 1 independent source, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.